Advertisement
Advertisement
SGMT
Sagimet Biosciences Inc. Series A Common Stock
4.98
USDSponsored
+0.36
+7.77%
Mar 26, 14:24 UTC -4
Open
SGMT Earnings Reports
Positive Surprise Ratio
SGMT beat 7 of 11 last estimates.
64%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.37
Implied change from Q4 25 (Revenue/ EPS)
--
/+32.14%
Implied change from Q1 25 (Revenue/ EPS)
--
/-33.93%
Sagimet Biosciences Inc. Series A Common Stock earnings per share and revenue
On Mar 11, 2026, SGMT reported earnings of -0.28 USD per share (EPS) for Q4 25, beating the estimate of -0.41 USD, resulting in a 30.10% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.80% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.37 USD, with revenue projected to reach -- USD, implying an increase of 32.14% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
What were Sagimet Biosciences Inc. Series A Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Sagimet Biosciences Inc. Series A Common Stock reported EPS of -$0.28, beating estimates by 30.1%, and revenue of $0.00, 0% as expectations.
How did the market react to Sagimet Biosciences Inc. Series A Common Stock's Q4 2025 earnings?
The stock price moved up 3.8%, changed from $5.53 before the earnings release to $5.74 the day after.
When is Sagimet Biosciences Inc. Series A Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Sagimet Biosciences Inc. Series A Common Stock's next earnings report?
Based on --
analysts, Sagimet Biosciences Inc. Series A Common Stock is expected to report EPS of -$0.37 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement